<div id="readability-page-1"><p>Shares of Absci Co. (NASDAQ:ABSI - Get Free Report) have received a consensus recommendation of &#34;Buy&#34; from the seven brokerages that are  covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating.  The average 1-year target price among brokerages that have covered the stock in the last year is $8.57.</p><p>A number of equities research analysts have recently commented on ABSI shares. KeyCorp reduced their price objective on shares of Absci from $6.00 to $5.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, January 8th. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $7.00 price target on shares of Absci in a research report on Friday, January 17th. Needham &amp; Company LLC initiated coverage on Absci in a research report on Wednesday, January 22nd. They issued a &#34;buy&#34; rating and a $9.00 price objective for the company. Finally, Guggenheim  restated a &#34;buy&#34; rating and set a $10.00 target price on shares of Absci in a research report on Tuesday, December 3rd.</p><p><b>View Our Latest Research Report on Absci</b></p><h2>Absci Stock Up 0.2 %</h2><p>Shares of ABSI opened at $4.72 on Tuesday. The company has a market capitalization of $542.14 million, a PE ratio of -5.08 and a beta of 2.11. The stock's 50-day moving average price is $3.33 and its two-hundred day moving average price is $3.69. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci has a 12 month low of $2.45 and a 12 month high of $6.72. </p><p>Absci (NASDAQ:ABSI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.05). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. During the same period in the prior year, the firm earned ($0.24) earnings per share.  On average, analysts anticipate that  Absci will post -0.89 EPS for the current year. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in shares of  Absci by 88.0% during the second quarter. Dimensional Fund Advisors LP now owns 125,089 shares of the company's stock valued at $385,000 after acquiring an additional 58,556 shares in the last quarter.  Bank of Montreal Can acquired a new stake in  Absci in the 2nd quarter valued at $527,000.  The Manufacturers Life Insurance Company bought a new stake in  Absci during the 2nd quarter valued at $100,000.  IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in  Absci during the third quarter worth $53,000.  Finally, Cherry Creek Investment Advisors Inc. bought a new position in shares of  Absci in the third quarter valued at $149,000. 52.05% of the stock is owned by institutional investors and hedge funds. </p><h2>Absci Company Profile</h2> (Get Free Report<p>Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Absci</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>Price Plunge in Roblox Presents Opportunity for Robust Gains</li><li>Do ETFs Pay Dividends? What You Need to Know</li><li>Billions in Buybacks: 4 Stocks Rewarding Shareholders Now</li><li>3 Tickers Leading a Meme Stock Revival</li><li>3 Steel Stocks to Gain Strength as Tariffs Reshape the Market</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJTSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Where Should You Invest $1,000 Right Now?</h2><p>Before you make your next trade, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p><p>They believe these five stocks are the five best companies for investors to buy now...</p><p>See The Five Stocks Here </p><h2>Should You Invest $1,000 in Absci Right Now?</h2><p>Before you consider Absci, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.</p><p>While Absci currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABSI

<p>Absci Co. (NASDAQ:ABSI) has received a consensus "Buy" rating from seven brokerages, with an average price target of $8.57. KeyCorp lowered its price target from $6.00 to $5.00, while HC Wainwright set a target of $7.00. Needham initiated coverage with a $9.00 target, and Guggenheim set a $10.00 target. Absci's shares opened at $4.72, with a market cap of $542.14 million. The company reported a quarterly EPS of ($0.24), missing estimates, and had a revenue of $1.70 million, below expectations.</p>

Market Beat

Absci

Absci Co. (NASDAQ:ABSI) Receives $8.57 Average Price Target from Brokerages